miR395e from Manihot esculenta Decreases Expression of PD-L1 in Renal Cancer: A Preliminary Study

Genes, Journal Year: 2025, Volume and Issue: 16(3), P. 293 - 293

Published: Feb. 27, 2025

Background/Objectives: microRNAs are small non-coding RNAs that regulate gene expression by inducing mRNA degradation or inhibiting translation. A growing body of evidence suggests miRNAs may be utilized as anti-cancer therapeutics targeting key genes involved in cancerous transformation and progression. Renal cell cancer (RCC) is the most common kidney malignancy. The efficient RCC treatments involve blockers immune checkpoints, including antibodies PD-L1 (Programmed Death Ligand 1). Interestingly, recent studies revealed cross-kingdom horizontal transfer plant into mammalian cells, contributing to modulation food ingestion. Here, we hypothesized modulated originating from edible plants. Methods: To verify this hypothesis, performed bioinformatic analysis identify mes-miR395e Manihot esculenta (cassava) a promising candidate miRNA could target PD-L1. regulation mediated predicted miRNA, synthetic mes-miR395 mimics were transfected lines derived tumors, followed evaluation using qPCR Western blot. Results: Transfection RCC-derived confirmed decreases cells at both protein levels. Conclusions: This preliminary study shows promise potential adjuvants supporting treatment.

Language: Английский

Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics

Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1361 - 1361

Published: April 18, 2025

Background/Objectives: Clear-cell renal cell carcinoma (ccRCC) is a heterogenous disease that can be classified into multiple molecular subtypes with differential prognosis and sensitivities to treatments based on their genomic, transcriptomic, proteomic, metabolic profiles. Patient-derived xenografts (PDXs) are high-fidelity cancer models because they maintain similar genotypes immunohistologic phenotypes the parental tumors respond standard-of-care therapies as expected. However, whether identified in ccRCC patient samples preserved PDX not clear. Our objective compare transcriptional proteomic profiles of our those patients identify both similarities distinctions between corresponding subtypes, so proper used when investigating subtypes. Methods: To match PDXs human we compared transcriptomic five established lab reported by group, well other groups, using hierarchical analysis, Principal Component Analysis (PCA), Permutation Correlation Analysis. The enrichment key pathways was determined Gene Set Enrichment Results: We found each resembles one closely at transcript protein levels. In addition, representing different show unique characteristics. Moreover, correlated pathway activities implicated progression therapy resistance. Conclusions: results suggest should mechanism resistance for This “matching” strategy will greatly facilitate clinical translation positive findings optimal management patients.

Language: Английский